BRINGING YOU INFORMATION.  PROVIDING YOU A PLATFORM.

 

 
THE PHARMA REVIEW (MAY – JUNE 2014)

Pioglitazone: Unneeded Controversy

Dr. Guru Prasad Mohanta

Introduction: Pioglitazone belongs to the antidiabetic group of medicines ‘thiazolidinediones (or glitazones)’ was approved in US in early 1999. The two other drugs of the same glitazone group are withdrawn or severely restricted of use. Troglitazone within three years of introduction was removed because of its liver toxicity. Rosiglitazone is banned in many countries including India because of its association with elevated risk of cardiovascular events like heart attack and heart failure. In USA it is not banned but available with restricted use. 

 

Go to Content Index Page

PHARMA REVIEW - ARTICLES ARCHIVE ( COMPLETE LIST)

 

The above content is an abstract only. For the full Article please contact:
KONGPOSH Publications Pvt. Ltd.
ICS House, C-19, Commercial Complex, SDA, Opp. IIT Gate, New Delhi, India -110016
Tel.: 26855839, 9811195411
Email: kongposhpub@gmail.com, Website: http://www.kppub.com

 
 
 
 

Copyright © KONGPOSH PUBLICATIONS Pvt. Ltd.